https://www.selleckchem.com/products/ldn-212854.html RESULTS In the present study, 150 common DEGs and 5 common DEMs were screened using a Venn diagram in R language. First, a total of 6812 target genes were identified from the overlapping DEMs. Second, 26 overlapping dysregulated genes from 150 overlapping DEGs and 6812 miRNA target genes were identified. Meanwhile, 43 miRNA-gene regulatory pairs were obtained between the 5 common DEMs and 26 dysregulated genes. Downregulation of miR-376a-3p significantly inhibited the proliferation of HUVECs via inducing apoptosis. Moreover, overexpression of miR-376a-3p markedly inhibited the growth of HUVECs via downregulating NRIP1. CONCLUSION In this study, miR-376a-3p-NRIP1 pair might involve in the progression of CAD, implying that miR-376a-3p may be a therapeutic target for the treatment of CAD. AJTR Copyright © 2020.Cullin-5 (CUL5), a scaffold protein in active cullin-RING ubiquitin ligase (CRL) complexes, is a member of the cullin family of proteins. The CUL5-type ubiquitin ligase can target multiple proteins involved in ubiquitination and proteasome degradation. CUL5 plays positive roles in regulating cell growth, proliferation and physiological and other processes in the human body. It has been found that the expression of CUL5 is significantly downregulated in various cancer cells, which affects the course of the cancers. Here, we reviewed the current data on the expression and role of CUL5 in both normal and cancer cells, its possible mechanisms, and its potential as a therapeutic target for cancers. AJTR Copyright © 2020.PARP inhibitor (PARPi) therapies have been approved for treating multiple germline BRCA mutated (gBRCAm) advanced cancers including metastatic pancreatic cancer. Although significantly prolonged progression-free survival was observed in gBRCAm pancreatic cancer patients, there was no improved overall survival. The underlined resistant mechanism to PARPi therapy is worth pursuing. Here, we reported a